Results 281 to 290 of about 1,150,712 (337)
Irisin is a crucial plasma biomarker and promising therapeutic target that reflects disease severity, pulmonary vascular remodeling status and clinical outcome in patients with pulmonary arterial hypertension (PAH). As a novel protective factor, irisin is downregulated in PAH. By ubiquitination, irisin promotes Enolase 1 degradation and suppresses cell
Na Sun+15 more
wiley +1 more source
Environmental interpretation of the impact of vehicle emissions on prostate cancer progression. [PDF]
An B+5 more
europepmc +1 more source
An Engineered Soluble Single‐Chain TCR Engager for KRAS‐G12V Specific Tumor Immunotherapy
This study develops a dimeric T cell receptor engager protein specific for tumor KRAS‐G12V mutation. The engager proteins are capable of mediating the formation of synapse between T cell and tumor cell and demonstrate substantial tumor suppression efficacy.
Keke Ma+14 more
wiley +1 more source
Advances and Challenges in Prostate Cancer Diagnosis: A Comprehensive Review. [PDF]
Kania E+5 more
europepmc +1 more source
Nrf2 isn't just a protector—it's a driver of cancer stemness. The study uncovers how arsenic‐activated Nrf2 directly upregulates KLF4, a key pluripotency factor, fueling oncogenic reprogramming. Through enhancer activation and self‐reinforcing loop, Nrf2 and KLF4 co‐opt gene networks linked to epithelial‐to‐mesenchymal transition and tumor growth ...
Ziwei Wang+9 more
wiley +1 more source
The Great Pretender: Xanthogranulomatous Prostatitis Mimicking Prostate Cancer. [PDF]
Patil AA, Kamble A, Potdar OV, Sharma S.
europepmc +1 more source
High QSOX2 enhances stemness, drug resistance, and metastasis of ESCC cells. QSOX2‐mediated disulfide bond modification activates mTOR/c‐Myc signaling. CAFs‐secreted IGF‐1 drives mTOR/c‐Myc/QSOX2 positive feedback loop. Combining Ebselen, rapamycin, and cisplatin induces tumor dormancy in mice.
Wo‐Ming Chen+12 more
wiley +1 more source
Transcriptomic and functional analysis of triphenyl phosphate exposure in prostate cancer progression. [PDF]
Cai L, Du G.
europepmc +1 more source
Advanced Microfluidics for Single Cell‐Based Cancer Research
Cutting‐edge microfluidic platforms are transforming single‐cell cancer research. This review highlights advanced technologies, from droplet microfluidics to tumour‐chips, that enable functional and spatial single‐cell analyses. By integrating biosensing, immune components, and patient‐derived materials, these systems offer new insights into tumour ...
Adriana Carneiro+10 more
wiley +1 more source